Barclays analyst Manav Patnaik maintains Gartner (NYSE:IT) with a Equal-Weight and lowers the price target from $325 to $265.
Scilex Announces Market Research Results Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB With Potential Advantages Compared To Calcitonin Gene-Related Peptide Products And Triptan Therapy
Migraines affect over 37 million Americans, according to the Migraine Research Foundation (MRF).1Migraine-related pain is the third most prevalent illness in the world.1According to the Global Burden of Disease study,
